Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. by Topham, C. et al.
Br. J. Cancer (1991), 64, 179 181 © Macmillan Press Ltd., 1991
Randomised trial ofepirubicin alone versus 5-fluorouracil, epirubicin and
mitomycin C in locally advanced and metastatic carcinoma of the pancreas
C. Topham', J. Glees2, N.S.B. Rawson3, E.M. Woods4 & R.C. Coombes4
'Department ofRadiotherapy, St Luke's Hospital, Guildford, UK; 2Department ofRadiotherapy, St George's Hospital, London,
UK; 'University ofSaskatchewan, Box 92 Saskatoon, Saskatchewan, Canada; 4Department ofMedical Oncology, Charing Cross
Hospital, London, UK.
Summary Sixty-nine unselected patients with locally advanced and metastatic carcinoma of the pancreas,
who had not received previous chemotherapy or radiotherapy were randomised to receive either 5-fluorouracil,
epirubicin and mitomycin C (FEM) or epirubicin. Survival was not significantly different in the two arms.
Toxic reactions (WHO grade > 3) in the FEM and epirubicin arm respectively included nausea (2) (4), severe
alopecia (1) (3) and leucopenia (1), (5), none of these were statistically significant. We therefore suggest that
combination chemotherapy should not be used in preference to single agent chemotherapy as standard
treatment for locally advanced or metastatic cancer of the pancreas.
At the present time, no systemic treatment can be accepted as
standard therapy for carcinoma of the pancreas. In general,
two conclusions emerge from the studies to date. Firstly,
there is no evidence that combination chemotherapy benefits
patients more than single agents (O'Connell, 1985). Secondly,
of the single agents, several appear to have comparable
activity, specifically 5-Fluorouracil, adriamycin (and
epirubicin) and mitomycin C (Cullinan et al., 1985). Recently
epirubicin has been shown to induce remission in a
significant proportion of patients with acceptable toxicity
(Wils et al., 1985) and we, therefore, embarked on a phase
III comparison of epirubicin and the combination epirubicin,
5-Fluorouracil and mitomycin C. The median survival for
both localised and metastatic carcinoma of the pancreas is
3-5 months (Gray et al., 1973) and, therefore, we decided to
enter both categories of patients in this study.
Patients, materials and methods
Sixty-nine patients were randomised to receive either
5-Fluorouracil, epirubicin and mitomycin C (FEM) or
epirubicin alone (Table I) given as follows:
5-Fluorouracil 1 g i.v. on days 1 and 28
Epirubicin 60 mg i.v. on days 1 and 28
Mitomycin C 10 mg i.v. on day 1
Cycle to be repeated every 8 weeks
Epirubicin lOOmgm2 every 4 weeks
The plan was to continue chemotherapy for 3 months. If a
response was documented treatment would continue for a
further four cycles. If there was evidence of progressive
disease at 3 months, treatment would be discontinued.
For patients to be eligible, they had to have a cytological
and histopathological diagnosis of pancreatic cancer. Subse-
quently, four patients were found to be ineligible for the
following reasons: no tumour (1), previous carcinoma (1),
and not adenocarcinoma of the pancreas (2). This left 65
patients of whom 31 were randomised to FEM and 34 to
epirubicin (Table I). Three of these 65 patients refused treat-
ment after randomisation (one in the FEM arm and two in
the epirubicin arm) and all that is known about them is their
date of death.
Table I Numbers of patients
FEM Epirubicin
Randomised 35 34
Ineligible 4 0
Eligible 31 34
Refused treatment 1 2
after randomisation
Results
The presenting symptoms are shown in Table II and are
similar in both groups. Of the 62 patients who received
therapy, a laparotomy was performed on all 32 patients
randomised to receive single agent therapy and 25 (83.3%) of
the 30 patients randomised to receive combination therapy
(Table III). Of these 57 patients, curative resection was
attempted in ten, palliative bypass was carried out in 35, and
the other 12 had a biopsy only.
Liver metastases were found in 12 patients (40.0%) in the
FEM group and in 14 (43.8%) in the epirubicin group. No
significant difference was seen in the level of the liver func-
tion tests in each group.
Table II Presenting symptomsa
FEM Epirubicin
Mass 7 (25.9%) 3 (9.7%)
Jaundice 15 (55.6%) 18 (58.1%)
Pain 18 (66.7%) 21 (67.7%)
Indigestion 4 (14.8%) 2 (6.5%)
Diarrhoea 3 (11.1%) 5 (16.1%)
Lethargy 6 (22.2%) 3 (9.7%)
Other 16 (59.3%) 14 (45.2%)
Any 27 (100.0%) 31 (100.0%)
aUnrecorded for three FEM patients and one epirubicin patient.
Table III Type of laparotomy performed
Laparotomy FEM Epirubicin
With resection 6 (24.0%) 4 (12.5%)
With bypass 14 (56.0%) 21 (65.6%)
With biopsy 5 (20.0%) 7 (21.9%)
Not done *5 0
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Number oftreatment courses given
The median numbers ofcourses of FEM and epirubicin given
to patients in this trial were 1.5 (range 0-11) and 2.5 (range
1-11) respectively. The number of FEM courses range from
zero because three patients who were randomised to receive
this treatment died before chemotherapy was administered.
Eighteen patients (60.0%) in the group randomised to receive
combination chemotherapy had less than three courses com-
pared with 12 patients (37.5%) in the epirubicin group; this
difference is not significant.
Response to chemotherapy
We laid down strict recommendations for assessing response,
i.e. CT scan or clinical documentation. Nevertheless,
insufficient clinical information was recorded for 12 patients
in the FEM group and six patients in the epirubicin group
and, hence, these were considered unevaluable for a response
assessment to be made. In the remaining 18 patients in the
FEM arm, two showed a partial response and the other 16
(88.9%) showed progressive disease (Table IV). Among the
26 assessable patients in the epirubicin arm, we recorded a
single responder and one patient showed a minimal response;
three patients showed stabilisation, but the other 21 patients
(80.8%) had progressive disease. This difference is not statis-
tically significant
Survival
Survival curves for the 65 eligible patients in the two ran-
domised groups are shown in Figure 1; there is no significant
difference between the two groups (log rank X2 = 0.36,
P = 0.55). The 1-year survival rates with (95% confidence
intervals) were 23.2% (8.6-42.7%) in the FEM and 15.4%
(5.1-31.7%) in the epirubicin groups respectively.
One patient who was randomised to receive FEM was
given epirubicin and one patient who was randomised to
receive epirubicin was given FEM. In addition, as mentioned
above, three patients who were randomised to receive FEM
died before chemotherapy was administered and three
patients refused treatment after randomisation (one to FEM
and two to epirubicin). Therefore, 27 patients actually
received FEM and 32 received epirubicin alone. Figure 2
shows the survival curves by treatment administered, but
again there is no significant difference (log-rank X2= 0.41,
P = 0.52).
The 6-month survival rate of patients without metastases
(70.0%; 95% CI 52.1-84.4%) was significantly greater
(P <0.05) than that of patients with metastases (18.0%;
95% CI 6.1-36.4%), but this difference of 52% between the
6-month survival rates declined to 1% at the 1-year point.
The median survival of the former group was 200 days,
whereas that of the latter was 74 days.
At the present time, there are seven patients alive in the
FEM arms (22.6%) compared with six in the epirubicin
(17.6%). There is no significant difference betwen the two
chemotherapy groups in this respect.
Toxicity
We graded the toxicity using the WHO scoring system and
two (7.4%) of the 27 patients treated with FEM had a
nausea score of three or more compared with four (12.5%)
of the 32 patients treated with single agent chemotherapy.
Table IV Response to chemotherapy
Response FEM Epirubicin
Not assessable 12 6
Assessed 18 26
Progressive disease 16 21
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Severe alopecia was seen in four patients (one in the FEM
arm and three in the epirubicin arm).
One patient in the FEM group had a white blood cell
count of less than 3 x i091-' compared with five patients in
the epirubicin group. There were no instances of septicaemia.
No platelet measurement was found to be less than
100 x I0'1-'. None of these toxicities were statistically
significant.
Discussion
The most significant feature that has emerged from this trial
is that single agent epirubicin is similar in terms of survival
to the FEM combination therapy (Figures 1 and 2). This,
together with the extra cost and discomfort to the patient
with combination therapy, suggests that it may be unneces-
sary to expose patients to multiple drugs to achieve some
form of palliation. Another surprising feature of this study is
that we were able to give such a small number of courses of
treatment to these patients. Nevertheless, we felt that it was
important to enter the majority of patients into the study
rather than select a minority of fit patients. This is a small
study, which has to be borne in mind when considering the
results; this fact is reflected in the wide confidence limits of
the 1-year survival rates. There are approximately 30 patients
in each arm of the trial and the minimum difference between
survival rates that would achieve significance at the conven-
tional 5% level with this number of patients is the order of
40%, e.g. a survival improvement from 10-50%. Such a
difference in effectiveness between two treatments in a cancer
clinical trial is extremely unlikely; one can usually expect a
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difference of only 5-10%. An improvement of the order of
40% would be so obvious that a clinical trial would not be
required.
Survival rates for patients with pancreatic cancer vary
depending on the type of operative techniques used, i.e. 1-
and 2-year survival rates for resected patients with localised
tumours are 23% and 20% compared with 1% and 0% for
non-operated patients (Gray et al., 1973). We, therefore,
checked that the distribution of types of surgical intervention
was similar in both treatment gorups. As one might expect,
patients with pancreatic cancer without metastases have a
better survival rate in the short term than those with metas-
tatic disease.
At the present time, the results of this trial lead us to
conclude that we cannot recommend combination chemo-
therapy as standard treatment for locally advanced or metas-
tatic cancer of the pancreas. We suggest that patients should
be treated with either single agent chemotherapy or palliative
treatment only. It has been shown that radiation, particularly
in symptom control, has a part to play (Komaki et al., 1988)
and a future trial may take this into consideration.
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